3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
6
Phase NA
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
43
Leukemia
7
Myelodysplastic Syndromes
4
Leukemia, Myelomonocytic, Chronic
4
Recurrence
2
Pathologic Complete Response
2
Neoplasms
2
MDS
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Myeloid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Higher-risk Myelodysplastic Syndrome
1
Hematologic Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Imatinib Mesylate
5
nilotinib
3
ponatinib
2
thymoglobulin
1
enasidenib
1
bosutinib
1
Transplantation
1
Standard of Care
1
Mycophenolic Acid
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone Acetate
1
Methylprednisolone
1
Hematopoietic Stem Cell Transplantation
1
Cytarabine
1
Cyclosporine
1
BID protein, human
1
Azacitidine
1
Antilymphocyte Serum
1
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Myeloid
×
Azacitidine
×
Clear all
NCT02577406
2025-05-18
IDHENTIFY
Celgene
Phase 3
Completed
319 enrolled
29 charts